Abstract
Background and aims Functional dyspepsia (FD) is a highly prevalent disorder of gut-brain interaction (DGBI) that is associated with an altered duodenal microbiota, unexplained low grade duodenal inflammation and altered intestinal permeability. This study aimed to investigate if novel FD-derived bacterial isolates elicited immune responses in FD and the capacity of an immune-stimulating isolate, AGIRA0003 to breach the duodenal epithelial barrier.
Methods Bacterial lysates were investigated for immune reactivity using immunoblotting of patient plasma. Immunoblots were probed with plasma from FD patients (n=44, 46.6±17.5 years, 79.6% female) or controls (n=30, 48.9±15.7 years, 63.3% female). Peripheral gut-homing T cells were quantified by flow cytometry and histological analysis used to investigate duodenal biopsies. Polarised Caco-2 cells and FD duodenal spheroids (n=4 lines) were exposed to Streptococcus salivarius AGIRA0003 at a multiplicity of infection of 10 bacterial cells to 1 mammalian cell for 6 hours.
Results The presence of plasma IgG antibodies against S. salivarius AGIRA0003 was significantly associated with FD (χ2 15.7, 1, p<0.0001). Patients with these IgG antibodies had increased gut-homing lymphocytes (0.33±0.77% vs 1.00±1.46%, p=0.046). Strain AGIRA0003, but not related commensal strains, disrupted tight junction proteins in Caco-2 monolayers, and decreased claudin 1 (CLDN1; 0.49±0.11, p=0.03), desmocollin 2 (DSC2; 0.64±0.33, p=0.03) and desmoglein 2 (DSG2; 0.30±0.12, p=0.03) in spheroid monolayers. In addition, DSC2 (2.19±0.97 vs 1.48±0.85, p=0.02) and DSG2 (23.22±15.92 vs 12.38±7.34, p=0.04) protein levels were decreased in IgG+ FD biopsies compared to controls.
Conclusions S. salivarius AGIRA0003 is a potential pathobiont capable of impairing duodenal epithelial barrier defences that elicits an immune response in FD patients.
Competing Interest Statement
GLB: Patent: Diagnostic marker for functional gastrointestinal disorders (Australian Patent Application PCT/AU2022/050556) via the University of Newcastle and UniQuest (University of Queensland). GH: Unrestricted educational support from Bayer Ptd, Ltd and the Falk Foundation. Research support was provided via the Princess Alexandra Hospital, Brisbane by GI Therapies Pty Limited, Takeda Development Center Asia, Pty Ltd, Eli Lilly Australia Pty Limited, F. Hoffmann-La Roche Limited, MedImmune Ltd Celgene Pty Limited, Celgene International II Sarl, Gilead Sciences Pty Limited, Quintiles Pty Limited, Vital Food Processors Ltd, Datapharm Australia Pty Ltd Commonwealth Laboratories, Pty Limited, Prometheus Laboratories, Falk GmbH and Co Kg, Nestle Pty Ltd, Mylan. Patent Holder: A biopsy device to take aseptic biopsies (US 20150320407 A1). PST: Listed as an inventor on multiple patents filed by the University of Newcastle and received funding for unrelated projects from EOFBIO, USA. The University of Newcastle holds financial interests in EOF-BIO, USA. MMW: Grant/research support: Prometheus Laboratories Inc (Irritable bowel syndrome [IBS] Diagnostic), Commonwealth Diagnostics International (biomarkers for FGIDs). MM: Patent: Diagnostic marker for functional gastrointestinal disorders (Australian Patent Application WO2022256861A1) via the University of Newcastle and UniQuest (University of Queensland). Research grants from Atmo Biosciences, Soho Flordis International (SFI) Australia Research, Bayer Consumer Health, and Yakult-Nature Global Grant for Gut Health; speakers honoraria, and travel sponsorship from Genie Biome, Janssen Australia; consultancy fees from Sanofi Australia and Danone-Nutricia Australia; speaker honoraria and travel sponsorship from Perfect Company (China), and travel sponsorship from Yakult Inc (Japan). MM also acknowledges funding from NHMRC Australia, Australian Research Council, Princess Alexandra Hospital Research Foundation, Medical Research Futures Fund of Australia, Helmsley Charitable Trust via the Australasian Gastrointestinal Research foundation, and United States Department of Defense. MM serves on the science advisory board (non-remunerated) for GenieBiome, Hong Kong. GJH reports to be on the advisory boards Australian Biotherapeutics, Glutagen, Bayer and received research support from Bayer, Abbott, Pfizer, Janssen, Takeda, Allergan. He serves on the Boards of the West Moreton Hospital and Health Service, Queensland, UQ Healthcare, Brisbane and the Gastro-Liga, Germany. He has a patent for the Brisbane aseptic biopsy device and serves as Editor of the Gastro-Liga Newsletter. NJT: Non-financial support from: Norgine (2021)(IBS interest group), personal fees from Allakos (gastroduodenal eosinophilic disease) (2021), Bayer (IBS) (2020), Planet Innovation (Gas capsule IBS) (2020), twoXAR Viscera Labs, (USA 2021) (IBS-diarrhoea), Dr Falk Pharma (2020) (EoE), Sanofi-aventis, Glutagen (2020) (celiac disease), IsoThrive (2021) (esophageal microbiome), BluMaiden (microbiome advisory board) (2021), Rose Pharma (IBS) (2021), Intrinsic Medicine (2022) (human milk oligosaccharide), Comvita Mānuka Honey (2021) (digestive health), Astra Zeneca (2022), outside the submitted work. In addition, Dr. Talley has a patent Nepean Dyspepsia Index (NDI) 1998, Biomarkers of IBS licensed, a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to Mayo/Talley, a patent Nestec European Patent licensed, and a patent Singapore Provisional Patent Microbiota Modulation of BDNF Tissue Repair Pathway issued, Diagnostic marker for functional gastrointestinal disorders Australian Patent Application WO2022256861A1via the University of Newcastle and UniQuest (University of Queensland). Committees: OzSage; NHMRC Principal Committee (Research Committee) Asia Pacific Association of Medical Journal Editors, Rome V Working Team Member (Gastroduodenal Committee), International Plausibility Project Co-Chair (Rome Foundation funded), COVID-19 vaccine forum member (by invitation only). Community group: Advisory Board, IFFGD (International Foundation for Functional GI Disorders), AusEE. Editorial: Medical Journal of Australia (Editor in Chief), Mayo Clinic Proceedings (Assoc Ed), Up to Date (Section Editor), Precision and Future Medicine, Sungkyunkwan University School of Medicine, South Korea, Med (Journal of Cell Press). Dr. Talley is supported by funding from the National Health and Medical Research Council (NHMRC) to the Centre for Research Excellence in Digestive Health and he holds an NHMRC Investigator grant. SK: Patent: Diagnostic marker for functional gastrointestinal disorders (Australian Patent Application WO2022256861A1) via the University of Newcastle and UniQuest (University of Queensland). Grants from National Health and Medical Research Council (Ideas Grant and Centre for Research Excellence), grants from Viscera Labs (Research contract), grants from Microba Life Science (Research contract), personal fees from Gossamer Bio, personal fees from Anatara Lifescience, personal fees from Immuron, personal fees from Microba Life Science. JW, ECH, KM, SS, JKB, WSS, SF, SC, JGA, ASW, MDE, ES Authors declare that they have no competing interests.
Funding Statement
National Health and Medical Research Council Centre for Research Excellence in Digestive Health (MMW, GH, MM, NJT, SK) National Health and Medical Research Council Ideas Grant (SK) National Health and Medical Research Council Investigator Grant (NJT) The Translational Research Institute is supported by a grant from the Australian Federal Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All work was carried out with approval from the Hunter New England Local Health District Ethics Committee (references 2019/ETH03893, 2020/ETH03303).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
: All data are available in the main text or the supplementary materials, further information is available from the authors upon reasonable request. S. salivarius AGIRA0003 sequence details can be found in E. C. Hoedt, E. R. Shanahan, S. Keely, A. Shah, G. L. Burns, G. J. Holtmann, N. J. Talley, M. Morrison, Draft Genome Sequence of Streptococcus salivarius AGIRA0003, Isolated from Functional Gastrointestinal Disorder Duodenal Tissue. Microbiol Resour Announc 10, e0075821 (2021).
